Pasithea Therapeutics Corp. (KTTAW) Stock Price & Analysis

Pasithea Therapeutics Corp. (KTTAW) Healthcare & Pipeline Overview

Pasithea Therapeutics Corp. is a biotechnology firm specializing in the research and development of treatments for psychiatric and neurological conditions, including plans for anti-depression clinics utilizing ketamine infusions. Operating in the competitive biotechnology sector, Pasithea focuses on innovative therapies for mental health disorders.

What Is the Investment Thesis for KTTAW?

Pasithea Therapeutics Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on psychiatric and neurological disorders addresses a significant and growing market need. Key value drivers include the successful development and commercialization of novel therapeutics, as well as the establishment and operation of anti-depression clinics. The company's small market capitalization and early stage of development contribute to significant volatility. Upcoming clinical trial results and regulatory milestones represent potential catalysts. A P/E ratio of -0.47 reflects the company's current lack of profitability. The company's beta of 0.20 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

KTTAW Key Highlights

Pasithea Therapeutics Corp. was incorporated in 2020, indicating its early stage of development.

• The company focuses on research and discovery of treatments for psychiatric and neurological disorders, addressing a significant market need.
• Plans to operate anti-depression clinics using ketamine infusions represent a potential revenue stream and service offering.
• The company's market capitalization is $0.00B, reflecting its small size and early stage.
• The company has a P/E ratio of -0.47, indicating it is not currently profitable.

Who Are KTTAW's Competitors?

KTTAW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KTTAW's Key Strengths?

Focus on a high-need area: psychiatric and neurological disorders.

• Plans to operate anti-depression clinics, offering a direct service.
• Innovative approach to mental health treatment using ketamine infusions.
• Relatively small size allows for agility and adaptability.

What Are KTTAW's Weaknesses?

Early stage of development with limited operating history.

• Small market capitalization and limited financial resources.
• Dependence on successful research and development outcomes.
• Reliance on regulatory approvals for drug development and clinic operations.

What Are the Key Risks for KTTAW?

Financial-distress signal — its Altman Z-Score of -2.25 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-49.5%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Clinical trial failures for novel therapeutics.
• Regulatory delays or rejections for drug approvals.
• Competition from established pharmaceutical companies.
• Dependence on securing additional funding for research and development.
• Negative publicity or safety concerns related to ketamine infusions.

What Threats Does KTTAW Face?

• Intense competition from established pharmaceutical companies.
• Regulatory hurdles and lengthy drug approval processes.
• Potential adverse effects or safety concerns related to ketamine infusions.
• Changes in healthcare regulations or reimbursement policies.

What Are KTTAW's Competitive Advantages?

• Proprietary research and development capabilities.
• Potential intellectual property protection for novel therapeutics.
• First-mover advantage in ketamine infusion therapy clinics.
• Expertise in psychiatric and neurological disorders.

What Does KTTAW Do?

Pasithea Therapeutics Corp., established in 2020 and headquartered in Miami Beach, Florida, is a biotechnology company dedicated to the research, discovery, and development of novel treatments for psychiatric and neurological disorders. The company's core focus lies in addressing unmet needs in mental health through innovative therapeutic approaches. Pasithea's business model includes not only drug development but also the planned operation of anti-depression clinics. These clinics aim to provide business support services, leveraging trained pharmacists to administer intravenous infusions of ketamine, a treatment showing promise in managing certain depressive conditions. Pasithea's strategy involves a dual approach: advancing its research pipeline and establishing a clinical presence. The company's research efforts are geared towards identifying and developing new chemical entities and therapeutic interventions for a range of psychiatric and neurological conditions. The planned clinics represent a direct service offering, potentially generating revenue and providing a platform for real-world data collection and treatment optimization. Pasithea is operating in a highly competitive environment, facing established pharmaceutical companies and other biotechnology firms pursuing similar therapeutic targets. The company's success will depend on its ability to secure funding, advance its research programs, navigate regulatory pathways, and effectively commercialize its products and services.

What Products and Services Does KTTAW Offer?

• Researches and discovers treatments for psychiatric disorders.
• Researches and discovers treatments for neurological disorders.
• Plans to operate anti-depression clinics.
• Provides business support services for mental health treatments.
• Administers intravenous infusions of ketamine.
• Focuses on innovative therapies for mental health.

How Does KTTAW Make Money?

• Develops and commercializes novel therapeutics for psychiatric and neurological disorders.
• Operates anti-depression clinics providing ketamine infusion therapy.
• Generates revenue through clinic services and potential future drug sales.

What Industry Does KTTAW Operate In?

Pasithea Therapeutics Corp. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for psychiatric and neurological disorder treatments is substantial and growing, driven by increasing prevalence of mental health conditions and advancements in neuroscience. Companies like Pasithea face competition from established pharmaceutical giants and smaller biotech firms, all vying for market share. The industry is subject to stringent regulatory requirements, with drug development and approval processes often lengthy and costly. Success hinges on scientific breakthroughs, effective clinical trials, and successful commercialization strategies.

Who Are KTTAW's Key Customers?

• Patients suffering from psychiatric disorders.
• Patients suffering from neurological disorders.
• Individuals seeking treatment for depression.
• Healthcare providers seeking innovative therapies.

8 transactions · 1 purchases, 0 sales, 7 other transactions · 8 identified insiders · available records within the last 180 days, newest dated Jun 17, 2026 (coverage not recorded). Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Return on equity for Pasithea Therapeutics Corp. stands at -49.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.2%, showing how much profit it generates from its asset base. A current ratio of 26.25 indicates the company holds enough short-term assets to cover its near-term obligations.

Pasithea Therapeutics Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.25 places it in the distress zone, a signal of elevated financial risk.

Pasithea Therapeutics Corp. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 827.7% below estimates on average.

Wall Street analysts project Pasithea Therapeutics Corp. revenue of about $0 for fiscal 2026, with EPS near $-0.76.

Company Profile

Pasithea Therapeutics Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Tiago Reis Marques. KTTAW has traded publicly since 2021.

KTTAW Financials

KTTAW Latest News

KTTAW Analyst Consensus

KTTAW MoonshotScore

What Investors Ask About Pasithea Therapeutics Corp. (KTTAW) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources